Anthony M. Manning - 11 Jun 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: Director
Issuer ticker: GLUE
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:05:14 UTC
Prior SEC filing: 22 May 2026
Next SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Markus Warmuth, Attorney-in-Fact

Key filing fact

Anthony M. Manning filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 12 Jun 2026.

Key facts

This page summarizes Anthony M. Manning's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001716468 Primary reporting owner

Manning Anthony M.

Relationship: Director
Address: MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON
Signature: /s/ Markus Warmuth, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLUE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +25,800
Change %
Price: $0.000000^*
Shares after: 25,800
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,800
Exercise price: $17.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.